Recursion reports Phase 2 FAP data, Sanofi option, Hassan as new chair
Third-quarter 2026 update details REC-4881 polyp reductions in FAP, early REC-1245 responses, a Sanofi development-candidate option, and cash runway extended into 2029.
SEC filing